Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 714-720

  Nguyen, Lee H ^a   Hsu, Donald I ^b   Ganapathy, Vaidyanathan ^c   Shriner, Kimberly ^d   Wong Beringer, Annie ^c,d  

^a LOMA LINDA UNIVERSITY   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Fluoroquinolone resistance; Prescribing changes; Reduced mortality

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; QUINOLONE DERIVATIVE; TAZOBACTAM; TOBRAMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SEPSIS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; EMPIRICAL RESEARCH; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 40049095115     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm510     Document Type: Article

References (19)

1. Gaynes R, Edwards J, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005; 41: 848-54.
2. Neuhauser M, Weinstein R, Rydman R et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003; 289: 885-8.
3. Aeschlimann J. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other Gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2003; 7: 916-2.
4. Aubert G, Pozzetto B, Dorche G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother 1992; 29: 307-12.
5. Hooper D. Efflux pumps and nosocomial antibiotic resistance: A primer for hospital epidemiologists. Clin Infect Dis 2005; 40: 1811-7.
6. Jacoby G. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: S120-6.
7. Zhanel G, Hoban D, Schurek K et al. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Int J Antimicrob Agents 2004; 24: 529-35.
8. Hsu D, Okamoto M, Murthy R et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: Risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005; 55: 535-41.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
10. Knaus W, Draper E, Wagner D et al. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-29.
11. Garner J, Jarvis W, Emori T et al. GDC definitions for nosocomial infections, 1988. Am J Infect Control 1998; 16: 128-40.
12. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A et al. Antimicrobial use and the influence of inadequate empiric antimicrobial therapy on the outcomes of nosocomial bloodstream infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2004; 25: 735-41.
13. Ibrahim E, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
14. Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8.
15. Kollef M, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
16. Gasink LB, Fishman NO, Weiner MG et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: Assessment of risk factors and clinical impact. Am J Med 2006; 119: 526.e19-25.
17. Nseir S, Di Pompeo C, Soubrier S et al: Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory faliure: A case-control study. Crit Care 2005; 9: R238-45.
18. Micek ST, Lloyd AE, Ritchie DJ et al. Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-11.
19. Kriengkauykiat J Porter E, Lomovskaya O et al. Use of an efflux-pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 565-70.